Sri Lanka, June 3 -- The Ministry of Health has clarified recent reports concerning the immunoglobulin drug manufactured by India's ICHOR Biologics Pvt Ltd. Registered in Sri Lanka in April 2023 after thorough evaluation by the National Medicines Regulatory Authority (NMRA), the drug faced temporary suspension following complaints about its quality.

Accordingly, the investigation by the National Drug Quality Assurance Laboratory and the Safety and Risk Assessment Subcommittee led to its withdrawal from use.

However, further analyses, including reports from India's Central Drug Quality Agency, confirmed that the drug met required standards. Consequently, the subcommittee recommended reinstating the drug for medical use.

The Ministry sa...